My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 500359 | NSE: RANBAXY | Pharmaceuticals & Drugs | Mid Cap
1. Is a good quality company?
Data is not available for this company.
2. Is undervalued or overvalued?
No data found
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | TTM | |||
| ROCE % ⓘ | 21.5% | 6.8% | 10.3% | 5.2% | 3.5% | 4.4% | 10.7% | -0.9% | 6.3% | -2.6% | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 3,720 | 3,565 | 4,030 | 4,136 | 4,470 | 4,780 | 5,670 | 7,799 | 6,304 | 5,492 | 5,571 | ||
| YoY Gr. Rt. % | - | -4.2% | 13% | 2.6% | 8.1% | 6.9% | 18.6% | 37.6% | -19.2% | -12.9% | - | ||
| Adj EPS ⓘ | 14.2 | 5 | 11.3 | 6.2 | 3.2 | 7.1 | 20.6 | -6.6 | 4.7 | -10.6 | -3.2 | ||
| YoY Gr. Rt. % | - | -64.7% | 124.1% | -44.6% | -49% | 124.2% | 189.2% | -132.1% | NA | -324.3% | - | ||
| BVPS (₹) ⓘ | 67.2 | 63.6 | 62.8 | 67.8 | 84.1 | 94 | 121.6 | 45.3 | 44.9 | 20.3 | 1.5 | ||
| Adj Net Profit ⓘ | 529 | 187 | 420 | 233 | 134 | 300 | 868 | -279 | 201 | -451 | -136 | ||
| Cash Flow from Ops. ⓘ | 411 | 107 | 315 | 686 | -390 | -665 | 1,169 | 128 | 662 | -974 | - | ||
| Debt/CF from Ops. ⓘ | 0.3 | 9.6 | 10.1 | 5.1 | -9.5 | -5 | 3.7 | 33.8 | 7.3 | -5.1 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 4.4% | 4.2% | -1.1% | -12.9% | ||||||||
| Adj EPS ⓘ | -196.8% | -227.3% | -180.2% | -324.3% | ||||||||
| BVPSⓘ | -12.5% | -24.7% | -44.9% | -54.8% | ||||||||
| Share Price | - | - | - | - | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | TTM | ||
| Return on Equity % ⓘ | 21.9 | 7.7 | 17.8 | 9.5 | 4.3 | 7.6 | 18.7 | -7.9 | 10.4 | -37.3 | -29.2 | |
| Op. Profit Mgn % ⓘ | 17.9 | 6.2 | 15.6 | 9.3 | 5.7 | 13.6 | 22.1 | 17.7 | 9.5 | -1.9 | 8.1 | |
| Net Profit Mgn % ⓘ | 14.2 | 5.3 | 10.4 | 5.6 | 3 | 6.3 | 15.3 | -3.6 | 3.2 | -8.2 | -2.4 | |
| Debt to Equity ⓘ | 0.1 | 0.4 | 1.4 | 1.4 | 1.1 | 0.9 | 0.8 | 2.3 | 2.5 | 5.8 | - | |
| Working Cap Days ⓘ | 222 | 221 | 205 | 222 | 238 | 281 | 296 | 299 | 411 | 375 | 0 | |
| Cash Conv. Cycle ⓘ | 77 | 98 | 105 | 116 | 101 | 105 | 93 | 107 | 175 | 107 | 0 | |
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -3.2 | -19.1 |
| TTM Sales (₹ Cr.) | 5,571 | 10,614 |
| BVPS (₹.) ⓘ | 1.5 | 59.8 |
| Reserves (₹ Cr.) ⓘ | -148 | 2,334 |
| P/BV ⓘ | 561.84 | 14.37 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 810.30 / 869.00 |
| All Time Low / High (₹) | 29.17 / 869.00 |
| Market Cap (₹ Cr.) | 36,603 |
| Equity (₹ Cr.) | 212.8 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 42.8 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
Ranbaxy has its R & D centre that helps company to have long term competitive advantage. It caters treatment to segment of diseases that includes Cardiovascular, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology.
Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatological, account for revenues of over $600 Million. Using the finest R&D and Manufacturing facilities, that manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, Active Pharmaceuticals and intermediates (API).
In 2001 Ranbaxy entered consumer healthcare through launch of 4 brands Revital, Pepfiz, Gesdyp & Garlic Pearls.
In 2004 launched its first herbal range of products through New Age Herbals (NAH), with products offering remedies in categories of Cough & Cold (Olesan Oil & Cough Syrups) and Appetite Stimulant (Eat Ease).
In 2005, another popular brand, Chericof - The complete cough formula was introduced. During 2006, the business registered sales of $19 Million registering a growth of 19%. Revital, the flagship brand continues to maintain leadership in its segment.
It also produces molecules like Simvastatin, Ciprofloxacin, Amoxycillin, Isotretinon and many more
In April 2014 Sun Pharmaceutical Industries Ltd and Ranbaxy Laboratories Ltd announced that they have entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. This exchange ratio represents an implied value of Rs 457 for each Ranbaxy share, a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014.
Milestone achieved
• 2013 -Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a new age cure for malaria
• 2012 - Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category
•2012 Launch India's first New Chemical Entity (NCE), SynriamTM, a new age cure for Malaria
• 2011 Launch Atorvastatin, a generic version of the world’s largest selling cholesterol lowering drug, in the US with 180-day market exclusivity
• 2011 - Ranbaxy is felicitated with the New Jersey Business and Industry Association Award for Excellence in the Business Expansion Category
• 2010 - Ranbaxy enters the Golden jublee year
• 2010- For the first time Ranbaxy delivered quarterly sales of over $500 million
• 2010 Launch First-to-File (FTF) product Donepezil hydrochloride tablets 5 mg and 10 mg with 180-day market exclusivity in the US Healthcare System
• 2009- Dailchi Sankyo and Ranbaxy announced reconstitution of Ranbaxy executive leadership. Ranbaxy was acquired by Daiichi Sankyo through acquisition of it 52.5% of the equity share capital.
• 2008- Ranbaxy partnered with Daiichi Sankyo Company to create a strategic combination of an innovator and generic powerhouse
• 2007- Ranbaxy has signed new R&D agreement with GSK
• 2006-Ranbaxy acquires generic unbranded business of GSK in Italy & Spain
• 2006 -Ranbaxy acquires Terapia largest independent generic pharma company in Romania for $ 324 million
• 2003 Ranbaxy receives The Economic Times award for corporate excellence for ‘The Company of the year’2002-03
• 2000 Ranbaxy acquires Bayers generic business in Germany. It has alliance with Glaxo SmithKline for Drug discovery & clinical development
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
